Genetic Technologies Limited · ASX:GTG
Genetic Technologies — H1 FY2023 Earnings Presentation
24 slides from Genetic Technologies's earnings presentation, Feb 28, 2023
Slide 1: FY23 Half-year Financial Results – Strong Revenue Growth Performance
ASX Market Announcement FY23 Half-year Financial Results – Strong Revenue Growth Performance For personal use only Melbourne, Australia, 28 February 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ: GENE, ”Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellne
Slide 2: Direct to Consumer, QIAGEN and scientific publications
Direct to Consumer (DTC) EasyDNA and AffinityDNA’s revenue base continue to grow. EasyDNA has focused on developing the Direct-to- Consumer (DTC) channel, which targets the growing DTC genetic testing market (global market expected to grow to US$2.6 billion by 2025 1). EasyDNA is set to relaunch a n
Slide 3: Registration Link, Enquiries and About Genetic Technologies
Registration Link: Participants are encouraged to register before the webinar using the details below. https://us02web.zoom.us/webinar/register/WN_06dvKDd7SCSD0Ceh5wCnNw For personal use only -END- Authorised for release by the board of directors of Genetic Technologies Limited. Enquiries Investor R
Slide 4: Genetic Technologies – Investor Webinar
For personal use only Genetic Technologies – Investor Webinar The Future: Unlocking personalised preventative medicine 28 February, 2023 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 5: World leading portfolio
World leading portfolio For personal use only Most comprehensive guideline driven portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic diseases • Pet care Revenues anchored by our 3
Slide 6: Comprehensive genomics-based testing via a multi-brand strategy
Comprehensive genomics-based testings via a multi-brand strategy For personal use only Medical & Payer Business Consumer initiated Direct to Consumer to Business (B2B) testing (CIT) Testing (DTC) with medical supervision with no medical supervision [insert Oncology – GTGrevenue structure and [insert
Slide 7: Global Overview
Global Overview For personal use only 57 40 25 Employees Countries Patents Granted* globally (9 Pending Worldwide*) 14 51 12 Test Categories Tests Partner Laboratories 4 * Patents granted are specific to the GeneType portfolio of products
Slide 8: Snapshot and Achievements last months
Snapshot and Achievements last 12 months For personal use only GeneType commercialization EasyDNA & Affinity DNA Reimbursement activation Phase 1 commercial release of the geneType Multi-Risk test Completed 2 Acquisitions Independently developed Budget Impact Model (BIM) in US identifies US$1.
Slide 9: Delivering Revenue and Growth – H1 FY23
Delivering Revenue and Growth – H1 FY23 For personal use only Cash Receipts (A$'000) H1 CASH RECEIPTS CASH BALANCE $4,456 67% Growth A$4.5m A$12.4m* on LY half-year$2,659 ending December 31, 2021 GROSS MARGIN GROSS MARGIN A$2.03m 45% H1 FY22 H1 FY23 Strategic and Operational Highlights: • Invited to
Slide 10: Execute the B2B commercialisation of the geneType multi-risk test
For personal use only Execute the B2B commercialisation of the geneType multi-risk test Commercialisation of the geneType suite of multi-risk tests Commercialisation of the geneType suite of multi-risk tests Our FOCUS Demonstrate clinical validity & clinical utility of geneType tests Core ‘4’ EasyDN
Slide 11: NEW Strategic Alliance with Qiagen
NEW Strategic Alliance with Qiagen The alliance will establish and develop a ‘Centre of Excellence’ facility in Australia For personal use only QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions, including: • Reagents and QIAGEN’s p
Slide 12: NEW Comprehensive Breast and Ovarian Cancer test
NEW Comprehensive Breast and Ovarian Cancer test Evaluates a woman’s risk of developing Breast and/or Ovarian Cancer in women 30 years+ For personal use only 5% - Hereditary Cancer with known pathogenic variant BRCA1/2 10% - Familial cancer with no known pathogenic variant 85% - GeneType Patented in
Slide 13: GeneType Priority Pathway to Market
GeneType Priority Pathway to Market For personal use only Medical & Payer Business Payer coverage is the key driver of revenues for geneType to Business (B2B) Coverage from payers in the US will accelerate adoption of geneType Risk Assessment Tests more widely Budget Impact Model (BIM) demonstrates
Slide 14: Economic Modeling in the US Payer System
Economic Modeling in the US Payer System1 The economic benefit to the payers in the US is US$1.4B per annum For personal use only $73 69% - 74% 6.8%-9.2% US Payor system will overall increase in women Supplemental screening save per patient per getting screened frequency year 14.8% - 8.8% 57% - 67%
Slide 15: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA For personal use only PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and agreement types] [insert revenue structure and agreement types] Brand Refresh Website Refresh Product list Improved Lead Gen New Sales Channels Product lis
Slide 16: eCommerce Growth strategy for EasyDNA
eCommerce Growth strategy for EasyDNA For personal use only 13
Slide 17: Thank you
For personal use only Thank you Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 14
Slide 18: Appendices
For personal use only Appendices 15
Slide 19: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Comm, FAICD, FCA, FGIA, Chairman Non – Executive Director FTIA, F Fin Non – Executive Director Non – Executive Director Dr. Jerzy “George”
Slide 20: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MWGO is MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, Primary Care Principal F
Slide 21: Financial Overview
Financial Overview For personal use only • Net cash outflow of A$6.7 million in H1 FY’23 (compared to H1 FY’22 outflow of: A$7.6 million) as we continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialise our geneType tests • Cash reserves will be directed to: A$’000 31-Dec-22
Slide 22: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 24 February 2023 0.4c ADR price (USD) as at 24 February 2023 $1.27 Other, 22% Ord Shares on Issue (M) 11,542 AS
Slide 23: Our Intellectual Property
Our Intellectual Property For personal use only 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of assessing risk of • Breast cancer risk assessment developing a severe response to Coronavirus infection • Methods for assessing risk of developing prostate can
Slide 24: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — H1 FY2023 Earnings Presentation on 6ix